S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Asterias Biotherapeutics Inc stock logo
AST
Asterias Biotherapeutics
$0.00
$0.00
$0.51
$2.05
$111KN/A136,653 shs1,000 shs
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
C$0.22
-4.3%
C$0.23
C$0.10
C$0.35
C$31.25M2.3840,331 shs61,047 shs
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
C$0.26
-3.8%
C$0.26
C$0.15
C$0.53
C$52.28MN/A644,760 shs384,329 shs
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
+2.22%-8.00%+6.98%+21.05%-11.54%
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Asterias Biotherapeutics Inc stock logo
AST
Asterias Biotherapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
N/AN/AN/AN/AN/AN/AN/AN/A
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Asterias Biotherapeutics Inc stock logo
AST
Asterias Biotherapeutics
N/AN/AN/AN/A
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
N/AN/AN/AN/A
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Asterias Biotherapeutics Inc stock logo
AST
Asterias Biotherapeutics
N/AN/AN/AN/AN/AN/A
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
C$324.55K96.28C$0.01 per share39.00C$0.02 per share11.00
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
C$13.02M4.02C$0.33 per share0.78C$0.40 per share0.64

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Asterias Biotherapeutics Inc stock logo
AST
Asterias Biotherapeutics
N/AN/A0.00N/AN/AN/AN/AN/A
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
-C$7.21M-C$0.21N/AN/AN/A-169.75%-45.14%6/26/2024 (Estimated)
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
N/A-C$0.70N/AN/AN/AN/AN/AN/A

Latest C4XD, EMH, AST, 4BB, and BU Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/14/2024Q3 2024
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
N/A-C$0.02-C$0.02-C$0.02N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Asterias Biotherapeutics Inc stock logo
AST
Asterias Biotherapeutics
N/AN/AN/AN/AN/A
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
N/AN/AN/AN/AN/A
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Asterias Biotherapeutics Inc stock logo
AST
Asterias Biotherapeutics
N/AN/AN/A
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
190.99
1.63
1.71
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
35.45
2.97
2.61

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Asterias Biotherapeutics Inc stock logo
AST
Asterias Biotherapeutics
N/A
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
0.33%
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Asterias Biotherapeutics Inc stock logo
AST
Asterias Biotherapeutics
N/A
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
29.93%
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Asterias Biotherapeutics Inc stock logo
AST
Asterias Biotherapeutics
N/A55.66 millionN/ANot Optionable
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
24142.03 millionN/ANot Optionable
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
161205.03 millionN/ANot Optionable

C4XD, EMH, AST, 4BB, and BU Headlines

SourceHeadline
University Hospitals Elyria Medical CenterUniversity Hospitals Elyria Medical Center
health.usnews.com - September 23 at 12:26 AM
Digital Therapeutics: Next wave in managing chronic medical conditionsDigital Therapeutics: Next wave in managing chronic medical conditions
health.economictimes.indiatimes.com - September 13 at 9:19 PM
The Digital Therapeutics Market Is GangbustersThe Digital Therapeutics Market Is Gangbusters
mddionline.com - August 29 at 11:45 PM
Digital Therapeutics (DTx) For Mental Health Market is Booming and Expected to Grow at a CAGR of 27.42% to 2031 | InsightAce StudyDigital Therapeutics (DTx) For Mental Health Market is Booming and Expected to Grow at a CAGR of 27.42% to 2031 | InsightAce Study
finance.yahoo.com - July 31 at 12:17 AM
Emerald Isle’s Lee Avenue to close again soon as culvert project restartsEmerald Isle’s Lee Avenue to close again soon as culvert project restarts
carolinacoastonline.com - July 15 at 8:44 AM
Efficient Market Hypothesis (EMH): Definition and CritiqueEfficient Market Hypothesis (EMH): Definition and Critique
investopedia.com - July 12 at 2:56 PM
Revolutionizing mental health treatment: Vistagen Therapeutics nasal spray solutionRevolutionizing mental health treatment: Vistagen Therapeutics' nasal spray solution
finance.yahoo.com - June 20 at 12:36 PM
Menarini Group Shares New Analysis from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Metastatic Breast Cancer at ASCO 2023Menarini Group Shares New Analysis from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Metastatic Breast Cancer at ASCO 2023
thaipr.net - May 29 at 4:23 AM
Emerald Care Center TulsaEmerald Care Center Tulsa
health.usnews.com - May 4 at 11:26 PM
Emerald ReegEmerald Reeg
health.usnews.com - April 25 at 7:35 AM
Emerald Expositions GAAP EPS of $0.06, revenue of $93.6MEmerald Expositions GAAP EPS of $0.06, revenue of $93.6M
msn.com - March 14 at 9:07 AM
Tahoes Emerald Bay freezes over for first time in decades amid atmospheric riverTahoe's Emerald Bay freezes over for first time in decades amid atmospheric river
sfgate.com - March 13 at 4:02 AM
Visus Therapeutics to Attend TD Cowen’s 43rd Annual Health Care ConferenceVisus Therapeutics to Attend TD Cowen’s 43rd Annual Health Care Conference
venturebeat.com - March 4 at 6:25 PM
Emerald community raising money for local dialysis services after political campaigns failEmerald community raising money for local dialysis services after political campaigns fail
abc.net.au - February 25 at 12:07 AM
New Digital Therapeutics Company Takes a Swing at FibromyalgiaNew Digital Therapeutics Company Takes a 'Swing' at Fibromyalgia
mddionline.com - February 22 at 11:25 PM
Emerald Asset Management PA, LLC 30th Annual Emerald Groundhog Day Investment Forum Opens Amid a Stormy 2023 Investment YearEmerald Asset Management PA, LLC 30th Annual Emerald Groundhog Day Investment Forum Opens Amid a Stormy 2023 Investment Year
finance.yahoo.com - January 14 at 1:43 PM
Emerald Health Therapeutics Inc (TBD.BE)Emerald Health Therapeutics Inc (TBD.BE)
finance.yahoo.com - January 4 at 3:42 AM
Emerald Health Therapeutics Announces Revocation of Management Cease Trade OrderEmerald Health Therapeutics Announces Revocation of Management Cease Trade Order
finance.yahoo.com - July 12 at 9:36 AM
Emerald Health Therapeutics, Inc. Reports 2021 Year-End Results and Corporate UpdateEmerald Health Therapeutics, Inc. Reports 2021 Year-End Results and Corporate Update
finance.dailyherald.com - July 4 at 7:56 AM
Emerald Health Therapeutics Provides Bi-Weekly MCTO Status UpdateEmerald Health Therapeutics Provides Bi-Weekly MCTO Status Update
finance.yahoo.com - June 16 at 8:02 AM
Emerald Health Therapeutics, Inc. Provides Bi-Weekly MCTO Status UpdateEmerald Health Therapeutics, Inc. Provides Bi-Weekly MCTO Status Update
stockhouse.com - May 16 at 4:37 PM
Skye Bioscience Signs Arrangement Agreement with Emerald Health TherapeuticsSkye Bioscience Signs Arrangement Agreement with Emerald Health Therapeutics
nz.finance.yahoo.com - May 12 at 9:26 AM
Cannabis Stock News: Emerald Health Therapeutics, Inc. (CSE: EMH) Transfers US Listing to OTCQBCannabis Stock News: Emerald Health Therapeutics, Inc. (CSE: EMH) Transfers US Listing to OTCQB
investorideas.com - May 6 at 10:47 AM
Emperor Oil Ltd (EMh)Emperor Oil Ltd (EMh)
investing.com - January 5 at 8:00 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Asterias Biotherapeutics logo

Asterias Biotherapeutics

NYSEAMERICAN:AST
Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California.
Burcon NutraScience logo

Burcon NutraScience

TSE:BU
Burcon NutraScience Corporation, together with its subsidiaries, develops plant proteins and ingredients for use in the food and beverage industries in Canada. The company offers Peazazz and Peazac, a pea protein for use in dairy alternatives, ready-to-drink beverages, dry blended beverages, bars, baked goods, and meat substitute products. It provides Puratein, a canola protein isolate for use in meat alternatives, such as burgers, sausages, and nutrition bars; Supertein, a canola protein that is a light-colored powder for use in non-dairy frozen desserts, egg alternative, plant-based marshmallows and ready-to-mix beverages, whipped toppings, and plant-based bars; and Nutratein, a canola protein comprising a mixture of globulin and albumin proteins for use in meat and egg alternatives, and other plant-based functional foods. In addition, the company offers Nutratein-PS, a blend of Peazazz pea protein and Supertein canola protein; Nutratein-TZ, a blend of Peazac pea protein and Puratein canola protein; and CLARISOY, a soy protein for use in sports nutrition beverages, citrus-based drinks, fruit-flavored beverages, lemonades, powdered beverage mixes, and non-beverage plant-based products. The company was formerly known as Burcon Capital Corp. and changed its name to Burcon NutraScience Corporation in October 1999. The company was incorporated in 1998 and is headquartered in Vancouver, Canada.
Emerald Health Therapeutics logo

Emerald Health Therapeutics

CVE:EMH
Emerald Health Therapeutics, Inc., together with its subsidiaries, produces and sells medical cannabis for medical purpose in Canada. The company is also involved in developing natural health products. It offers dried cannabis strains, pre-rolls, and cannabis oil products to its medical patients. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Vancouver, Canada.